12th international conference on human retrovirology: HTLV and related retroviruses

Please use this identifier to cite or link to this item: http://hdl.handle.net/1811/47423

Show full item record

Files Size Format View
LairmoreM_Retrovirology_2005_2_61.pdf 220.2Kb PDF View/Open

Title: 12th international conference on human retrovirology: HTLV and related retroviruses
Creators: Lairmore, Michael D.; Fujii, Masahiro
Issue Date: 2005-10-04
Publisher: BioMed Central
Citation: Michael D. Lairmore and Masahiro Fujii, "12th international conference on human retrovirology: HTLV and related retroviruses," Retrovirology 2 (2005), doi:10.1186/1742-4690-2-61, http://www.retrovirology.com/content/2/1/61
DOI: 10.1186/1742-4690-2-61
Abstract: The 12th International Conference on Human Retrovirology: HTLV and Related Retroviruses, was held at the Half Moon Hotel in Montego Bay, Jamaica, from June 22nd to June 25th 2005. The scientific conference, sponsored by the International Retrovirology Association, is held biennially at rotating international venues around the world. The meeting brings together basic scientists, epidemiologists and clinical researchers to discuss findings to prevent HTLV infection or develop new therapies against HTLV-mediated diseases. The Association fosters the education and training of young scientists to bring new approaches to the complex problems of HTLV research, such as translational research to bring findings from the laboratory into clinical trials that benefit HTLV-infected patients. The breadth and quality of research presentations and workshops at the 12th International Conference indicate that these goals are being accomplished. As HTLV research enters its third decade a new generation of scientists face many challenges. However, HTLV scientists and clinicians displayed exciting new approaches and discoveries during plenary talks and poster sessions. The conference encouraged research in HTLV infections and disease, fostered collaborations, and stimulated new partnerships between clinicians and scientists to encourage clinical trials and novel therapeutic interventions.
ISSN: 1742-4690
URI: http://hdl.handle.net/1811/47423
Bookmark and Share
Attribution 3.0 Unported This item is licensed under a Creative Commons License:
Attribution 3.0 Unported